From the Guidelines
The EMERALD-1 trial demonstrated that the combination of TACE plus durvalumab and bevacizumab significantly improved progression-free survival (PFS) in TACE-eligible patients, with a median PFS of 15 months compared to 8.2 months for TACE plus placebo. The study met its primary endpoint of improved PFS, with a hazard ratio (HR) for PFS of 0.77 (95% CI 0.61-0.98) 1. The trial recruited patients irrespective of tumor size and number, provided all lesions could be treated within a 16-week period. The interim analysis for overall survival (OS) did not show a statistically significant difference, and the trial is ongoing for the final analysis of OS. The EMERALD-1 trial provides evidence for the efficacy of combining TACE with immunotherapy using durvalumab and bevacizumab, which may lead to improved outcomes for patients with hepatocellular carcinoma (HCC). Some key points from the study include:
- The combination of TACE plus durvalumab and bevacizumab improved PFS in TACE-eligible patients
- The median PFS was 15 months for the combination arm and 8.2 months for the TACE plus placebo arm
- The HR for PFS was 0.77 (95% CI 0.61-0.98)
- The trial is ongoing for the final analysis of OS The EMERALD-1 trial is a significant study in the field of HCC treatment, and its findings may have implications for the management of patients with this disease.
From the Research
EMERALD-1 Study Findings
There are no research papers to assist in answering this question as the provided studies do not mention the EMERALD-1 study.
- The studies provided discuss the efficacy and safety of darolutamide in various prostate cancer settings, including nonmetastatic castration-resistant prostate cancer 2, 3 and metastatic hormone-sensitive prostate cancer 4, 5.
- However, none of the studies mention the EMERALD-1 study, making it impossible to provide findings on this specific study.
- Further research or information would be needed to determine the findings of the EMERALD-1 study.